Short interest in Rigel Pharmaceuticals Inc (NASDAQ:RIGL) increased during the last reporting period, rising from 1.85M to 2.08M. This put 11.96% of the company's publicly available shares short.

Almost a year to the day after Roche pulled out a partnership on its underperforming cancer therapy Gavreto, Blueprint Medicines has sold US commercial rights to the drug to Rigel Pharma in a deal ...

Visit a quote page and your recently viewed tickers will be displayed here.

Get the latest news and real-time alerts from Rigel Pharmaceuticals, Inc. (RIGL) stock at Seeking Alpha. Skip to content Home page Seeking Alpha - Power to Investors ...

Rigel Pharmaceuticals, Inc. (RIGL) earnings report: revenue, EPS, surprise, history, news and analysis. Skip to content Home page Seeking Alpha - Power to Investors ...